Metabolic Health
Explore peptides researched for metabolic regulation, weight management, and glucose homeostasis, including GLP-1 receptor agonists and related compounds.
19 articles
Semaglutide and the GLP-1 Revolution: What Researchers Need to Know
A comprehensive research overview of semaglutide, the GLP-1 receptor agonist that has reshaped metabolic health research with over 169 PubMed studies, $29.3B in revenue, and expanding clinical applications from weight management to cardiovascular outcomes.
Semaglutide vs Tirzepatide: GLP-1 Agonist Comparison
A comprehensive comparison of semaglutide and tirzepatide, the two leading GLP-1 receptor agonists. Examine clinical trial data, mechanisms, efficacy, side effects, cost, and FDA approval status.
Tirzepatide: The Dual GIP/GLP-1 Receptor Agonist Reshaping Metabolic Research
A comprehensive research overview of tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound. Explore its mechanism, SURMOUNT and SURPASS trial data, $16.5B revenue trajectory, and how it compares to semaglutide.
Retatrutide: The Triple Agonist Setting New Records in Obesity Research
A research-focused overview of retatrutide (LY3437943), the investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly that achieved 23.7% body weight reduction in Phase 2 trials, the largest ever recorded in an obesity trial.
The Complete Guide to GLP-1 Receptor Agonists: From Semaglutide to Retatrutide
An in-depth comparison of every major GLP-1 receptor agonist in research and clinical development, including semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide, survodutide, and mazdutide. Mechanism differences, efficacy data, and market positions.
What Is Semaglutide? A Research Overview
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most studied compounds for weight management and metabolic health.
What Is Tirzepatide? A Research Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents a new class of incretin-based therapeutics for type 2 diabetes and obesity management.
Liraglutide: The First-Generation Daily GLP-1 That Paved the Way
A comprehensive overview of liraglutide (Saxenda/Victoza), the first-generation daily GLP-1 receptor agonist with 97% homology to human GLP-1 that established the foundation for the entire class of incretin-based metabolic therapies.
AOD-9604: The Modified Growth Hormone Fragment for Fat Metabolism Research
A detailed research overview of AOD-9604, the modified fragment of human growth hormone (amino acids 177-191) investigated for its lipolytic properties and potential to promote fat metabolism without the systemic effects of full-length GH.
Fat Loss Peptides: AOD-9604, HGH Fragment, and Metabolic Research
A research-focused overview of peptides investigated for fat loss applications, including AOD-9604, HGH Fragment 176-191, Adipotide, Tesamorelin, 5-Amino-1MQ, and MOTS-c. Compares GLP-1, GH-fragment, and direct fat-targeting approaches.
HGH Fragment 176-191: The Unmodified Growth Hormone Lipolytic Fragment
A research overview of HGH Fragment 176-191, the unmodified C-terminal fragment of human growth hormone studied for its lipolytic properties, its relationship to AOD-9604, and the current state of the evidence.
Tesamorelin: The GHRH Analog for Visceral Fat Reduction Research
A comprehensive research overview of tesamorelin (Egrifta), the growth hormone-releasing hormone analog FDA-approved for HIV-associated lipodystrophy, its mechanism of stimulating the GH axis, and its research applications in visceral fat reduction.
MOTS-c: The Mitochondrial Peptide Linking Exercise, Metabolism, and Aging
A comprehensive research overview of MOTS-c, the mitochondrial-derived peptide that has emerged as a key research focus in metabolism, aging, and exercise science. Covers its unique origins, AMPK activation mechanism, exercise mimetic properties, and relationship to aging.
Pramlintide: The Amylin Analog for Diabetes and Satiety Research
A thorough research overview of pramlintide (Symlin), the synthetic amylin analog FDA-approved for diabetes management. Explore its unique mechanism of slowing gastric emptying, suppressing glucagon, and promoting satiety signaling.
Cagrilintide: The Long-Acting Amylin Analog Behind CagriSema
A research overview of cagrilintide, Novo Nordisk's investigational long-acting amylin analog designed for weekly dosing and studied in combination with semaglutide as CagriSema for enhanced weight management.
Survodutide: The Dual Glucagon/GLP-1 Agonist Targeting Liver Disease
A research overview of survodutide, the investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim being developed for obesity and NASH/MASH, with a focus on its hepatic fat reduction potential.
Mazdutide: The Dual GLP-1/Glucagon Agonist From Innovent Biologics
A research overview of mazdutide (IBI362), the dual GLP-1/glucagon receptor agonist developed by Innovent Biologics for the Chinese and global markets, with Phase 3 data showing significant weight loss and metabolic improvements.
Adipotide (FTPP): The Fat Vasculature-Targeting Peptide With Primate Data and Safety Concerns
A detailed research overview of adipotide (FTPP/prohibitin-targeting peptide), the chimeric peptide that targets white fat tissue vasculature for apoptosis, examining its dramatic primate weight loss data alongside significant safety and toxicity concerns.
Pancragen: The Pancreatic Bioregulator Tetrapeptide and Beta-Cell Research
A research overview of Pancragen (Lys-Glu-Asp-Trp), a tetrapeptide bioregulator from the Khavinson series targeting pancreatic tissue, with particular focus on beta-cell function and glucose metabolism research.
For informational purposes only. Not medical advice. Always consult with qualified healthcare professionals.